REDLAMP 4: Circulating Tumor DNA & CT Monitoring for Untreated DLBCL – A Correlative Biomarker Study

First-line chemotherapy for diffuse large B-cell lymphoma is given with curative intent, but is not always effective. In this video, Dr. Peter Martin discusses the implications of a recently published study in Lancet Oncology, which aimed to discover whether a blood test capable of detecting circulating tumor DNA might predict treatment success or failure. In the future, blood tests may be added to, or even replace, current standard surveillance methods like CT scans or PET scans.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible. View all posts by lymphomaprogram